Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)

Merck & Co., Inc. (NYSE:MRK) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET

Company Participants

Jannie Oosthuizen – President
Peter Dannenbaum – Senior Vice President, Investor Relations
Marjorie Green – SVP, Head of Oncology Clinical Development

Conference Call Participants

Tim Anderson – Bank of America

Tim Anderson

Thanks for joining us for this, meeting. I’m Tim Anderson, the U.S. large-cap pharma and biotech analyst at Bank of America. We have the pleasure of speaking with Merck today.

Three folks on stage, Jannie Oosthuizen, did I get it right, who’s president U.S., Human Health. He’s held this role since 2022. He joined Merck in 2014, serving various roles internationally as well.

Most recently led global marketing for oncology. And prior to Mark, you were at Lilly for, a long time, I think, 20 years.

Jannie Oosthuizen

Yeah. We have Doctor Marjorie Green, Senior Vice President, Head of Oncology Clinical Development at Merck. She joined the company in 2023 from Cision. And then, of course, we have Peter Dannenbaum, Investor Relations, who many of you will have known. And Peter, you joined Merck. When, what year was that now?

Peter Dannenbaum

2017.

Question-and-Answer Session

Q – Tim Anderson

Okay. 2017. So, we’re going to start off with some policy questions and same questions you’ve heard me ask many others, and I know some of these will be difficult to answer. Lots of headlines on lots of different things, MFN being the most recent topic. How much time is that taking internally from you, let’s say?

Peter Dannenbaum

Yes. It’s taking a fair amount of time. I think right now, it’s a question of not just what are you hearing and seeing, but what are you potentially missing, right? So, I think we definitely do spend a lot of time.